Back to Search
Start Over
A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens
- Source :
- British Journal of Haematology. 176:440-447
- Publication Year :
- 2016
- Publisher :
- Wiley, 2016.
-
Abstract
- Summary Clinical trials of vorinostat, a Class I/II histone deacetylase inhibitor, in combination with proteasome inhibitors and immunomodulatory agents have shown activity in relapsed/refractory multiple myeloma. This phase IIb, open-label, single-institution study evaluated the efficacy of vorinostat in combination with lenalidomide and dexamethasone in lenalidomide-refractory patients. Patients were considered lenalidomide-refractory if they had no clinical response (
- Subjects :
- Male
Oncology
medicine.medical_specialty
Population
Neutropenia
Pharmacology
Hydroxamic Acids
Dexamethasone
Disease-Free Survival
03 medical and health sciences
0302 clinical medicine
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
education
Lenalidomide
Vorinostat
Multiple myeloma
Aged
Aged, 80 and over
Salvage Therapy
education.field_of_study
business.industry
Remission Induction
Hematology
Middle Aged
medicine.disease
Thalidomide
Regimen
Treatment Outcome
030220 oncology & carcinogenesis
Female
Multiple Myeloma
business
Progressive disease
030215 immunology
medicine.drug
Subjects
Details
- ISSN :
- 00071048
- Volume :
- 176
- Database :
- OpenAIRE
- Journal :
- British Journal of Haematology
- Accession number :
- edsair.doi.dedup.....ed8f6cb29cc27967a5b12194cd57df76